Universität zu Köln

Boell, Boris, Pluetschow, Annette, Buerkle, Carolin, Atta, Johannes, Pfreundschuh, Michael, Feuring-Buske, Michaela, Vogelhuber, Martin, Soekler, Martin, Eichenauer, Dennis A., Thielen, Indra, von Tresckow, Bastian, Fuchs, Michael, Engert, Andreas and Borchmann, Peter (2019). Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial. Br. J. Haematol., 185 (1). S. 42 - 53. HOBOKEN: WILEY. ISSN 1365-2141

Full text not available from this repository.

Abstract

About 30% of all Hodgkin lymphoma (HL) patients are >= 60 years old. As lenalidomide has promising single agent activity in multiple relapsed HL, we replaced bleomycin in ABVD with lenalidomide in this phase-I trial. Patients aged >= 60 years with early-unfavourable- or advanced-stage HL (Eastern Cooperative Oncology Group performance status <= 2, Cumulative Illness Rating Scale for Geriatrics score 0-7) received 4-8 cycles of AVD (doxorubicin, vinblastine, dacarbazine) and lenalidomide in escalation with overdose control. Dose-limiting toxicities (DLTs) included thromboembolism >= grade 2, severe haematological toxicity, neutropenic fever and prolonged therapy delay. Twenty-five patients with a median age of 68 years were included, 68% had advanced-stage HL. A pre-defined stopping criterion for dose escalation after DLT evaluation of 20/24 patients suggested a recommended phase II dose (RPTD) of 20 mg. DLTs occurred in 10/24 evaluable patients, all treated with >= 20 mg, however, median relative dose intensity was 97% (interquartile range 49-104%). Grade 3 or higher toxicities occurred in all 22 patients at >= 20 mg lenalidomide but no treatment-related deaths occurred. Overall response rate was 80% for all patients (20/25) and 86% (19/22) at >= 20 mg lenalidomide. Three-year estimates for progression-free survival and OS were 69 center dot 7% (95% CI: 50 center dot 3-89 center dot 1%) and 83 center dot 8% (95%-CI: 69 center dot 3-98 center dot 4%), respectively. In conclusion, AVD with lenalidomide 20 mg is feasible and highly effective in older HL patients.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Boell, Boris UNSPECIFIED UNSPECIFIED UNSPECIFIED Pluetschow, Annette UNSPECIFIED UNSPECIFIED UNSPECIFIED Buerkle, Carolin UNSPECIFIED UNSPECIFIED UNSPECIFIED Atta, Johannes UNSPECIFIED UNSPECIFIED UNSPECIFIED Pfreundschuh, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Feuring-Buske, Michaela UNSPECIFIED UNSPECIFIED UNSPECIFIED Vogelhuber, Martin UNSPECIFIED UNSPECIFIED UNSPECIFIED Soekler, Martin UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichenauer, Dennis A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Thielen, Indra UNSPECIFIED UNSPECIFIED UNSPECIFIED von Tresckow, Bastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Fuchs, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-152784
DOI:	10.1111/bjh.15741
Journal or Publication Title:	Br. J. Haematol.
Volume:	185
Number:	1
Page Range:	S. 42 - 53
Date:	2019
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1365-2141
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language AGED 60 YEARS; ELDERLY-PATIENTS; COMPREHENSIVE ANALYSIS; BRENTUXIMAB VEDOTIN; RANDOMIZED-TRIAL; BLEOMYCIN; ABVD; CHEMOTHERAPY; CYCLOPHOSPHAMIDE; COMBINATION Multiple languages Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/15278